Crossing the fourth hurdle
- 8 May 2012
- journal article
- review article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 73 (6) , 855-860
Abstract
The fourth hurdle, the requirement that pharmaceutical manufacturers can demonstrate that their new products represent good value for money as well as being of good quality, effective and safe, is increasingly being required by healthcare systems. In crossing this ‘fourth’ hurdle, companies will usually need to demonstrate that their products are more effective than relevant comparators and that the increased cost is offset by the enhanced benefits. Decision makers, however, must draw their conclusions not only on the basis of the underpinning science but also on the social values of the people they serve.Keywords
This publication has 12 references indexed in Scilit:
- Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysisThe Lancet, 2011
- Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological studyBMJ, 2011
- Network Meta-Analysis with Competing Risk OutcomesValue in Health, 2010
- Indirect Comparisons: A Review of Reporting and Methodological QualityPLOS ONE, 2010
- Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviewsBMJ, 2009
- Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysisThe Lancet, 2009
- Simultaneous comparison of multiple treatments: combining direct and indirect evidenceBMJ, 2005
- Pharmacopolitics and deliberative democracyClinical Medicine, 2005
- Indirect comparisons of competing interventionsHealth Technology Assessment, 2005
- National Institute for Clinical Excellence and its value judgmentsBMJ, 2004